1. Home
  2. KZIA

KZIA

Kazia Therapeutics Limited

Logo Kazia Therapeutics Limited

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Founded: 1994 Country:
Australia
Australia
Employees: N/A City: NEW SOUTH WALES 2113
Market Cap: 9.6M IPO Year: 1999
Target Price: $2.00 AVG Volume (30 days): 902.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.36 EPS Growth: N/A
52 Week Low/High: $0.19 - $1.68 Next Earning Date: 04-30-2024
Revenue: $15,650 Revenue Growth: -99.85%
Revenue Growth (this year): 97726.09% Revenue Growth (next year): N/A

Share on Social Networks: